about
Development of Liposomal Ciprofloxacin to Treat Lung InfectionsInhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road aheadPolymeric nanocarriers for transport modulation across the pulmonary epithelium: dendrimers, polymeric nanoparticles, and their nanoblendsAdvances in device and formulation technologies for pulmonary drug delivery.Efficacy of liposome-encapsulated ciprofloxacin in a murine model of Q fever.Investigation of the Changes in Aerosolization Behavior Between the Jet-Milled and Spray-Dried Colistin Powders Through Surface Energy Characterization.Inhaled antibiotics to treat lung infection.Advances in inhaled technologies: understanding the therapeutic challenge, predicting clinical performance, and designing the optimal inhaled product.Nanoparticle-mediated pulmonary drug delivery: a reviewLiposomal antibiotic formulations for targeting the lungs in the treatment of Pseudomonas aeruginosa.Nebulizers for drug delivery to the lungs.Generation of tailored aerosols for inhalative drug delivery employing recent vibrating-mesh nebulizer systems.Inhaled antibiotics in the treatment of non-cystic fibrosis bronchiectasis: clinical and drug delivery perspectives.Fasudil and SOD packaged in peptide-studded-liposomes: Properties, pharmacokinetics and ex-vivo targeting to isolated perfused rat lungs.Aerosol Performance and Stability of Liposomes Containing Ciprofloxacin Nanocrystals.Aerosol performance and long-term stability of surfactant-associated liposomal ciprofloxacin formulations with modified encapsulation and release properties.Cell permeable peptide conjugated nanoerythrosomes of fasudil prolong pulmonary arterial vasodilation in PAH rats.Nebulised antibiotherapy: conventional versus nanotechnology-based approaches, is targeting at a nano scale a difficult subject?Drug delivery to the lungs: challenges and opportunities.Surviving nebulization-induced stress: dexamethasone in pH-sensitive archaeosomes.Hetero-Multivalency of Pseudomonas aeruginosa Lectin LecA Binding to Model Membranes.Phospholipids in pulmonary drug delivery
P2860
Q26764772-464F70A7-5B6F-4425-A194-213CFE47C3A9Q26822988-F570517A-EE5D-4A1C-9595-A5E7E953F41EQ33574188-BE836B32-F473-4CEB-B74E-86B8B073D1C5Q33962567-C0CC1EBF-7FA0-4EEE-B16D-4C17EA6C5A54Q34057550-42C07B48-781F-40B4-91C8-AEB8148228DCQ36642374-02454F0D-6F5B-46FD-8E64-A942FA44262FQ38162996-D4A9AEA6-2519-47A7-9DDD-C223BB0D1898Q38185862-447A47D0-DEF7-46F0-9623-6F7C3924F046Q38203377-4DAB0F1D-5894-401E-811C-FDF310CF06B0Q38214155-31933DD2-6A0D-466F-9E04-902541207C25Q38298171-8B0B23C8-F790-4231-8370-3983F3B5D852Q38498038-50137B20-CD93-4475-AF37-769592A7F0C5Q38569772-D2D4CE95-DB5C-4314-A050-9B26CA0CE36EQ40854694-6A2651C3-AF4F-4EFF-B60B-6158487A46AEQ41603902-BA1C840F-38F5-4815-8929-8F55AE85DF5FQ41608294-101B47B5-2FA9-420E-998A-0FE46BE966C3Q42275475-6AD32F2D-0E26-4322-9E85-40B4D120D119Q47122978-9E1FD6F6-CDC3-4BFB-BBD9-50423F1C7FB0Q47825882-966DE503-FBA7-4C26-B03C-37D54AA0CAEAQ51227992-67F253DB-EE9B-4528-86C6-F980921167DEQ55072854-9E9808F5-25FA-4DA5-929E-AD29CB3875B2Q59089495-55D0EA41-45BB-4482-9BC4-25E8617017BB
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Liposomal formulations for inhalation.
@en
type
label
Liposomal formulations for inhalation.
@en
prefLabel
Liposomal formulations for inhalation.
@en
P2860
P356
P1433
P1476
Liposomal formulations for inhalation.
@en
P2093
Igor Gonda
P2860
P304
P356
10.4155/TDE.13.71
P577
2013-08-01T00:00:00Z